Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
21 hedge funds and large institutions have $36.4M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
63% more capital invested
Capital invested by funds: $22.3M → $36.4M (+$14.1M)
11% more funds holding
Funds holding: 19 → 21 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
+$2.93M |
| 2 |
DM
Deerfield Management
New York
|
+$1.71M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.22M |
| 4 |
JP Morgan Chase
New York
|
+$760K |
| 5 |
DA
DSC Advisors
Chicago,
Illinois
|
+$300K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$617K |
| 2 |
SM
Senvest Management
New York
|
-$382K |
| 3 |
Millennium Management
New York
|
-$188K |
| 4 |
Jennison Associates
New York
|
-$99.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$89K |
FOMX Hedge Fund Activity: Q4 2014 in Review
21 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2014, worth a combined $36.4M — up 63% from $22.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FOMX positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Senzar Asset Management, opening a new position worth an estimated $2.93M. The largest seller was Sabby Management, cutting an estimated $617K.
- 21 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2014, up from 19 in Q3 2014.
- Funds reported $36.4M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2014, up 63% quarter-over-quarter.
- 9 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2014 and 5 closed out, a net change of +4 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2014 was Senzar Asset Management, an estimated $2.93M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2014 was Sabby Management, an estimated $617K sold.
Based on aggregated 13F filings for Q4 2014.